Actively Recruiting
Observational Study for the Evaluation of Immune-mediated Endocrinological Adverse Events in Patients With Hematological Malignancies and Subjected to Treatment With Immune-checkpoint Inhibitors
Led by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Updated on 2025-02-28
100
Participants Needed
1
Research Sites
26 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Retrospective / prospective observational study of endocrinological adverse events in hematologic patients treated with immunological checkpoint inhibitors
CONDITIONS
Official Title
Observational Study for the Evaluation of Immune-mediated Endocrinological Adverse Events in Patients With Hematological Malignancies and Subjected to Treatment With Immune-checkpoint Inhibitors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged over 18 years
- Diagnosis of mature lymphoproliferative syndrome of B or T lymphocyte origin
- Advanced stage of illness (relapsed or refractory)
- Patients treated with or candidates for immune checkpoint inhibitor therapy
- Written informed consent provided
You will not qualify if you...
- Severe acute or chronic medical or psychiatric disorders that may affect study results or interfere with participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
IRCCS Azienda Ospedaliero - Universitaria di Bologna
Bologna, Bologna, Italy, 40138
Actively Recruiting
Research Team
P
Pier Luigi Zinzani, MD
CONTACT
C
Cinzia Pellegrini, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here